Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages 3083-3090

  Metzger Filho, Otto ^a   Sun, Zhuoxin ^b   Viale, Giuseppe ^b   Price, Karen N ^c   Crivellari, Diana ^d,f   Snyder, Raymond D ^g   Gelber, Richard D ^b   Castiglione Gertsch, Monica ⁱ   Coates, Alan S ^h,j   Goldhirsch, Aron ^e   Cardoso, Fatima ^k  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g ST VINCENT S HOSPITAL   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY HOSPITAL   (Switzerland)

^j International Breast Cancer Study Group   (Switzerland)

^k Champalimaud Cancer Center   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GOSERELIN; METHOTREXATE; TAMOXIFEN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INCIDENCE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST TUMOR; CHEMISTRY; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; FEMALE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84886502077     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.1574     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
2. Pestalozzi BC, Zahrieh D, Price KN, et al: Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935-944, 2006.
3. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996.
4. Grann VR, Troxel AB, Zojwalla NJ, et al: Hormone receptor status and survival in a populationbased cohort of patients with breast carcinoma. Cancer 103:2241-2251, 2005.
5. Kennecke H, Yerushalmi R, Woods R, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277, 2010.
6. Pagani O, Price KN, Gelber RD, et al: Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century. Breast Cancer Res Treat 117: 319-324, 2009.
7. Dent R, Hanna WM, Trudeau M, et al: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423-428, 2009.
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses oflong-term outcome among 100, 000 women in 123 randomised trials. Lancet 379:432-444, 2011.
9. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
10. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23, 2011.
11. International Breast Cancer Study Group (IBCSG): Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph nodenegative breast cancer: A randomized trial. J Natl Cancer Inst 94:1054-1065, 2002.
12. Karlsson P, Sun Z, Braun D, et al: Long-term results of International Breast Cancer Study Group Trial VIII: Adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 22:2216-2226, 2011.
13. Colleoni M, Cole BF, Viale G, et al: Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28: 2966-2973, 2010.
14. Viale G, Giobbie-Hurder A, Regan MM, et al: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569-5575, 2008.
15. Viale G, Regan MM, Mastropasqua MG, et al: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207-212, 2008.
16. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010.
17. Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes: Dealing with the diversity of breast cancer-Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747, 2011.
18. Fisher RA: The logic of inductive inference. J R Stat Soc 98:39-82, 1935.
19. Kruskal WH, Wallis WA: Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583-621, 1952.
20. Allison PD: Survival Analysis Using the SAS System: A Practical Guide. Cary, NC, SAS Institute, 2005.
21. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999.
22. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000.
23. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001.
24. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003.
25. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003.
26. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96, 2006.
27. Kim MJ, Ro JY, Ahn SH, et al: Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217-1226, 2006.
28. Fulford LG, Reis-Filho JS, Ryder K, et al: Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Res 9:R4, 2007.
29. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006.
30. Calza S, Hall P, Auer G, et al: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8:R34, 2006.
31. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9:R16, 2007.
32. Voduc KD, Cheang MC, Tyldesley S, et al: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691, 2010.
33. Hess KR, Pusztai L, Buzdar AU, et al: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118, 2003.
34. Alanko A, Heinonen E, Scheinin T, et al: Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56:1696-1700, 1985.
35. Smid M, Wang Y, Zhang Y, et al: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114, 2008.
36. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 22:3608-3617, 2004.
37. Miller KD, Weathers T, Haney LG, et al: Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 14: 1072-1077, 2003.
38. Dawood S, Broglio K, Esteva FJ, et al: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20:621- 627, 2009.